HITV Therapy|東京のがん免疫療法なら【ICVS東京クリニック】まで


HITV Therapy
- Human Initiated Therapeutic Vaccine -

Click here for Inquiry
to ICVS Tokyo Clinic

[Consultation Appointments and Inquiries]
ICVS Tokyo Clinic welcomes patients by appointment only.
If you would like a consultation for the treatment of yourself or your family member, please have the patient's most recent PET-CT images ready. And then send an appointment request using the inquiry form. We start communicating with you by emails and asking you to send the CD-ROM to ICVS Tokyo Clinic.


Immune System and Dendritic Cells

In the immune system, Dendritic Cells learn and acquire information on foreign substances to attack and convey this information to immune cells in charge of the attack. Immune cells with high attacking ability attack enemy foreign substances based on the information provided by Dendritic Cells. Therefore, in order for immune cells to mount an effective attack against foreign substances (tumor cells), it is important for Dendritic Cells to have accurate and precise information.


How HITV Therapy Works

01Dendritic Cells are injected directly into the tumor.
Highly antigenic cancer information enables highly precise cancer attack. In HITV therapy, Dendritic Cells are injected directly into the tumor with our unique adjuvant (a substance that activates Dendritic Cells), while confirming with CT images during the treatment.
This ICVS-unique advanced method of introducing Dendritic Cells directly into the body allows the Dendritic Cells to collectively learn and acquire information on multiple cancers in the patient's own tumor with greater accuracy and precision.
02Vaccinating the Tumor: Turning the tumor itself into an immune-cell-production factory.
Dendritic Cells injected into tumors by HITV therapy recognize information on cancer cells with high precision, so that instructions to immune cells attacking cancer cells are also precise.
CTLs (killer T cells/cytotoxic T lymphocytes), which are representatives of offensive immune cells, are induced in the body around the second week after the administration of Dendritic Cells and begin to attack cancer cells based on the information from the Dendritic Cells.
Being given the precise cancer information, these CTLs continue to attack cancer cells for 24 hours restlessly. In other words, the tumor itself, directly injected with Dendritic Cells, becomes a factory that produces CTLs that attack cancer cells, resulting in the "vaccination of the tumor."
03Our HITV Therapy cleanses even the tiniest cancer cells: Removes cancer cells from the blood and prevents metastasis and recurrence.
Even if a tumor mass is removed by surgery or radiation, microscopic cancer cells that cannot be identified by diagnostic imaging remain, and they migrate through the bloodstream, implant, and become cancerous. And the possibility of recurrence will not disappear unless all cancer cells in the blood are removed.

In our HITV therapy, the tumor keeps producing attacking-immune-cell CTLs, and highly accurate CTLs are constantly flowing out of the vaccinated tumor into the bloodstream, which travel throughout the body in the blood and launch a powerful attack immediately upon detection of cancer cells. This action leads to the prevention of cancer metastasis and recurrence.

Greetings from
our new Director of
ICVS Tokyo Clinic,
Dr. Jun Hasumi, MD.

Jun Hasumi

I am pleased to take up the position of Director of ICVS Tokyo Clinic as of April 2024.
Since assuming the Deputy Director in September of last year, I have been deepening my commitment to the development of immunotherapy by utilizing my experience and knowledge in cancer treatment.
In taking on this responsible position, I deeply feel that it is not my strength alone, but with the cooperation of all clinic staff and the warm support of patients and their families.
I sincerely ask for your continued support and cooperation.

Greetings from
Dr. Kenichiro Hasumi,
MD, and CEO of
ICVS Tokyo Clinic

The time has finally come when we can expect cancer shrinkage or disappearance by IMMUNOTHERAPY alone for advanced cancer.
In the future, IMMUNOTHERAPY is expected to be the main player of cancer treatment, being supported by anticancer drugs and radiotherapy to speed up the healing process.
In the aging society, IMMUNOTHERAPY with fewer side effects will enable people to lead meaningful lives while maintaining their quality of life (QOL) without incurring great costs.
As I have treated patients from more than 15 countries and regions so far, ICVS Tokyo Clinic welcomes inquiries from people overseas.


Note: English speaking doctorsare at workbut not assured to attendyour visit.

Chairman, ICVS Tokyo Clinic Kenichiro Hasumi, M.D.

Dr. Kenichiro Hasumi is a physician, specializing in cancer immunotherapy and terminal care. Graduated from Saitama Medical University. After working at the Institute of Medical Science, University of Tokyo, he became the Chairman and CEO of Hasumi International Research Foundation in USA. He is by nature a researcher and visionary, focused on the development of cancer vaccines and improved clinical treatments to achieve better patient outcomes with a higher quality of life.
He established a research chair at Thomas Jefferson University's Sidney Kimmel Cancer Center, USA, and was a visiting professor at the Cancer Center. He received an honorary doctorate from the Medical University of Pleven, Bulgaria, for his research activities in cancer immunotherapy. He is also involved in collaborative research projects with University of Maryland in USA, Erlangen University in Germany, and clinical trials with Universiti Kebangsaan Malaysia (UKM), respectively.

Director, ICVS Tokyo Clinic Jun Hasumi, M.D.

Graduated from the Jikei University School of Medicine in 2016, Dr. Jun Hasumi had been with the Jikei University Hospitals for about 7 years. He is a specialist in radiology as well as in diagnostic radiology.
Concurrently he has been working at ICVS Tokyo Clinic as a part-time physician since 2020, and also became a member of the Board of Hasumi International Research Foundation in USA.
In September 2023, he was appointed Deputy Director of ICVS Tokyo Clinic.

Doctor Yasuko Kusaka, M.D., Ph.D.

Dr. Kusaka, specializing in neurosurgery, a certified industrial physician, and with a diploma in mountain medicine, graduated from Tohoku University School of Medicine, joined the Department of Neurosurgery, Tohoku University Hospital.
Clinical Training Abroad to Phoenix Neurosurgery in USA and Hanover Neurosurgery in Germany has led her to become a lecturer at the Department of Neurosurgery, the Jikei University School of Medicine in 2004.
She was appointed Director of ICVS Tokyo Clinic in 2018 and served there till March 2021.
She has been the Director of ICVS Tokyo Clinic V2 since December 2022.

Doctor Akira Takeuchi, M.D., Ph.D. Director ofHigashi Ginza Luke Clinic

After graduating from Saitama Medical University in 1989, he demonstrated "near-infrared laser bone density measurement theory" with the cooperation of the Agency of Industrial Science and Technology, Ministry of International Trade and Industry (then), and in 1994 received a doctorate from Saitama Medical University Graduate School (Department of Endocrinology).
He was in charge of research and treatment of far-infrared hyperthermia (heat therapy), and in 1997 opened Luke Clinic, specializing in advanced cancer treatment.
He introduced cancer ablation therapy (HIFU:high-intensity focused ultrasound) using focused ultrasound and apoptosis sensitization therapy using p53 protein.

Japan Hyperthermia Society instructor

Doctor Sakuzo William Honjo, M.D.

After graduating from the Jikei University School of Medicine, he joined the Department of Radiology at the University. During his tenure, he engaged in image diagnosis and IVR treatment. Wanting to utilize the experience and know-how he had gained in IVR, after leaving the department, he has been working at the ICVS Tokyo Clinic since May 2023.
"I am committed to providing safe procedures with minimal patient burden."

Please read before proceeding to the Inquiry:
Conditions for HITV Therapy Treatment:
1. HITV therapy is indicated for patients with recurrent cancer or advanced cancer diagnosed as stage IV.
2. The details of the indications for each patient will be explained at the preliminary diagnosis.

Cancers / Tumors not applicable for HITV Therapy
The following patients are not eligible for HITV therapy.

* Patients with blood cancers such as leukemia
* Patients who lack basic physical fitness (e.g., those who have difficulty in self-ambulation or oral intake, cholinesterase level less than 200, etc.)

Medical Coordinating Agents
ICVS Tokyo Clinic asks patients to come with professional support of "medical coordinating agents (outside contractors)" to ensure smooth progress of HITV treatment.
If you like, we can introduce one of our outside medical coordinators.

No Attending Physician System
The doctor in charge will be decided by the Clinic depending on the reservation of the day. There is no attending physician system.


INQUIRY : Your Information

First Name
Last Name
Your Email Address
Are you the patient?

Below: Patient's Information

First Name
Last Name
Country of Citizenship
Country of Residence
Birth Date
Year : Month : Date :
Cancer Name :
Cancer Stage :
Available Data
Please specify the data you can offer to the Clinic, and the date of the test.

Date of the test :
Please specify :
Inquiries to ICVS Tokyo Clinic

Payment Information (Settlement from overseas):

SWIFT Code :
Bank Name :
MUFG Bank, Ltd.
Branch Name :
Kojimachi-Chuo Branch
Account Type :
Savings account
Account Number :
Account Name :
Tokyo Clinic and Research Institute ICVS Incorporated